Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity 
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
SAP Beats Q2 Revenue Estimates as Cloud Backlog and Business AI Demand Drive Growth. 
Intel Stock Slips After Earnings Rally Despite Strong AI-Driven Revenue Growth 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Oracle Stock Rises After Winning Up to $6.99 Billion U.S. Defense Software Contract 
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Coca-Cola Raises Diet Coke Prices in India as Iran Conflict Disrupts Can Supply 
OpenAI AI Agent Reportedly Breached Hugging Face, Raising AI Safety Concerns 
Uber Stock Falls as Waymo Plans to End Robotaxi Partnership by 2028 
AMD Unveils Helios AI Servers to Challenge Nvidia as OpenAI Adopts New Platform 
Trump Administration Monitors OpenAI Incident as Lawmakers Push AI Kill Switch Bill 
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
